Millennium Management’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
Other funds holding GALT
WANY
Millennium Management's GALT Position: Q2 2026 in Review
Millennium Management reduced its Galectin Therapeutics (GALT) stake by 96% in Q2 2026, selling an estimated $1.98M and leaving 35,863 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #5368.
Millennium Management first reported a position in GALT in Q1 2014 and has held it in 35 quarters since. The position peaked at $2.23M in Q1 2026. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Millennium Management held 35,863 shares of Galectin Therapeutics worth $166K as of Q2 2026.
- Millennium Management sold 762,571 Galectin Therapeutics shares in Q2 2026, an estimated $1.98M.
- Galectin Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #5368 holding.
- Millennium Management first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 35 quarters since.
- Millennium Management's Galectin Therapeutics position peaked at $2.23M in Q1 2026.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.